The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Pashov A.I.

Immanuel Kant Baltic Federal University

Matsakova D.D.

Immanuel Kant Baltic Federal University

Volkova L.V.

Non-state private educational institution of higher education «Moscow University «Synergy»

Rachkovskaya V.V.

ArsMedica LLC

Turdieva A.S.

Immanuel Kant Baltic Federal University

Use of gonadotropic releasing hormone agonists in hyperplastic syndrome in gynecology

Authors:

Pashov A.I., Matsakova D.D., Volkova L.V., Rachkovskaya V.V., Turdieva A.S.

More about the authors

Journal: Russian Bulletin of Obstetrician-Gynecologist. 2025;25(4): 51‑58

DOI: 10.17116/rosakush20252504151

Read: 958 times

Buy for 300₽
Contact the author
Table of contents

USE OF GONADOTROPIC RELEASING HORMONE AGONISTS IN HYPERPLASTIC SYNDROME IN GYNECOLOGY
USE OF GONADOTROPIC RELEASING HORMONE AGONISTS IN HYPERPLASTIC SYNDROME IN GYNECOLOGY

To cite this article:

Pashov AI, Matsakova DD, Volkova LV, Rachkovskaya VV, Turdieva AS. Use of gonadotropic releasing hormone agonists in hyperplastic syndrome in gynecology. Russian Bulletin of Obstetrician-Gynecologist. 2025;25(4):51‑58. (In Russ.)
https://doi.org/10.17116/rosakush20252504151

Подписка 2026 Российский вестник акушера-гинеколога (Russian Bulletin of Obstetrician-Gynecologist)
МСФ на ЯМ
Использование инфографики авторами научных работ
Recommended articles:
Comparative analysis of the effe­ctiveness of therapy for endo­metrial hype­rplasia in women of reproductive age. Russian Bulletin of Obstetrician-Gynecologist. 2025;(2):75-83
Expe­rience of using anti-adhesive barriers in colo­rectal rese­ctions in connection with deep infi­ltrative endo­metriosis. Russian Bulletin of Obstetrician-Gynecologist. 2025;(5):81-86
Live birth rates after conservative treatment of atypical hype­rplasia and initial endo­metrial cancer. Russian Journal of Human Reproduction. 2025;(1):78-85
Expe­rience with the use of amitriptyline for chro­nic pelvic pain asso­ciated with endo­metriosis. Russian Journal of Human Reproduction. 2025;(1):86-93
Obje­ctification of Pain in Patients with Endo­metriosis. (Literature review and own data). Russian Journal of Human Reproduction. 2025;(2):62-85
The role of macrophage pola­rization in the deve­lopment of endo­metriosis and the therapeutic pote­ntial of its modu­lation. Russian Journal of Human Reproduction. 2025;(3):20-33
Morpho-functional features of the endo­metrium in uterine leiomyoma before and after embo­lization of the uterine arte­ries. Russian Journal of Archive of Pathology. 2025;(4):13-23
Expe­rimental mode­ling and treatment of endo­metriosis using bovhyaluronidase azoximer in an animal model. Russian Journal of Human Reproduction. 2025;(4):26-40
Deep endo­metriosis — a comparative study of pain syndrome and the prevalence of clinical symptoms acco­rding to the #ENZIAN classification. Russian Journal of Human Reproduction. 2025;(4):96-101
Abstract:

This article raises current issues of the use of gonadotropin-releasing hormone (GnRH) in women suffering from hyperplastic conditions in gynecology. Such diseases include: uterine fibroids, endometriosis, endometrial hyperplasia, and endometrial cancer. The article pays special attention to the pathophysiological aspects of the action of this hormone, reveals its positive pharmacological properties, as well as negative, undesirable properties (side effects). Some etiopathogenetic aspects of the development of hyperplastic diseases in gynecology and the points of influence of GnRH on them are touched upon. This article examines the general principles of pharmacological treatment of hyperplastic processes with GnRH, and also compares it with other drugs: the advantages and disadvantages of treatment methods are described.

Keywords:

GnRH agonists
hyperplastic processes
uterine myoma
endometriosis
endometrial cancer
endometrial hyperplasia

Authors:

Pashov A.I.

Immanuel Kant Baltic Federal University

Matsakova D.D.

Immanuel Kant Baltic Federal University

Volkova L.V.

Non-state private educational institution of higher education «Moscow University «Synergy»

Rachkovskaya V.V.

ArsMedica LLC

Turdieva A.S.

Immanuel Kant Baltic Federal University

Received:

29.04.2025

Accepted:

30.04.2025

Close metadata

References:

  1. Stamatiades GA, Kaiser UB. Gonadotropin regulation by pulsatile GnRH: Signaling and gene expression. Mol Cell Endocrinol. 2018;463:131-141.  https://doi.org/10.1016/j.mce.2017.10.015
  2. Ciccone NA, Kaiser UB. The biology of gonadotroph regulation. Curr Opin Endocrinol Diabetes Obes. 2009;16:4:321-327.  https://doi.org/10.1097/MED.0b013e32832d88fb
  3. Kumar P, Sharma A. Gonadotropin-releasing hormone analogs: Understanding advantages and limitations. J Hum Reprod Sci. 2014;7:3:170-174.  https://doi.org/10.4103/0974-1208.142476
  4. LiverTox: Clinical and research information on drug-induced liver injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Gonadotropins. 2018. PMID: 31644163.
  5. Sagsveen M, Farmer JE, Prentice A, Breeze A. Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density. Cochrane Database Syst Rev. 2003;2003:4:CD001297. https://doi.org/10.1002/14651858.CD001297
  6. Miinistry of Health of the Russian Federation. Clinical recommendations. Endometriosis. 2020. (In Russ.).
  7. Vigano P, Candiani M, Monno A, Giacomini E, Ver Cellini P, Somigliana E. Time to redefine endometriosis including its pro-fibrotic nature. Hum Reprod. 2018;33:3:347-352. 
  8. Vercellini P, Viganò P, Somigliana E, Fedele L. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol. 2014;5:261-275.  https://doi.org/10.1038/nrendo.2013.255
  9. Brown J, Farquhar C. Endometriosis: an overview of Cochrane Reviews. Cochrane Database Syst Rev. 2014;2014:3:CD009590. https://doi.org/10.1002/14651858.CD009590.pub2
  10. Dunselman GAJ, Vermeulen N, Becker C, Calhaz-Jorge C, D’Hooghe T, De Bie B, Heikinheimo O, Horne AW, Kiesel L, Nap A, Prentice A, Saridogan E, Soriano D, Nelen W; European Society of Human Reproduction and Embryology. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014;29:3:400-412.  https://doi.org/10.1093/humrep/det457
  11. Dlugi AM, Miller JD, Knittle J. Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Lupron Study Group. Fertil Steril. 1990;54:3:419-427.  https://doi.org/10.1016/s0015-0282(16)53755-8
  12. Bedaiwy MA, Alfaraj S, Yong P, Casper R. New developments in the medical treatment of endometriosis. Fertil Steril. 2017;107:3:555-565.  https://doi.org/10.1016/j.fertnstert.2016.12.025
  13. Ling FW. Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Pelvic Pain Study Group. Obstet Gynecol. 1999;93:51-58. 
  14. Mitwally MF, Gotlieb L, Casper RF. Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome. Menopause. 2002;9:4:236-241.  https://doi.org/10.1097/00042192-200207000-00004
  15. Szendei G, Hernádi Z, Dévényi N, Csapó Z. Is there any correlation between stages of endometriosis and severity of chronic pelvic pain? Possibilities of treatment. Gynecol Endocrinol. 2005;21:2:93-100.  https://doi.org/10.1080/09513590500107660
  16. Fernandez H, Agostini A, Baffet H, Chabbert-Buffet N, Descamps P, Estrade JP, Giraudet G, Hocke C, Salle B, Tremollieres F, Chapron C. Update on the management of endometriosis-associated pain in France. J Gynecol Obstet Hum Reprod. 2023;52:9:102664. https://doi.org/10.1016/j.jogoh.2023.102664
  17. Gallagher JS, Missmer SA, Hornstein MD, Laufer MR, Gordon CM, DiVasta AD. Long-term effects of gonadotropin-releasing hormone agonists and add-back in adolescent endometriosis. J Pediatr Adolesc Gynecol. 2018;31:4:376-381.  https://doi.org/10.1016/j.jpag.2018.03.004
  18. Nirgianakis K, Bersinger NA, McKinnon B, Kostov P, Imboden S, Mueller MD. Regression of the inflammatory microenvironment of the peritoneal cavity in women with endometriosis by GnRHa treatment. Eur J Obstet Gynecol Reprod Biol. 2013;170:2:550-554.  https://doi.org/10.1016/j.ejogrb.2013.08.010
  19. Olive DL. Optimizing gonadotropin-releasing hormone agonist therapy in women with endometriosis. Treat Endocrinol. 2004;3:2:83-89.  https://doi.org/10.2165/00024677-200403020-00003
  20. Loverro G, Carriero C, Rossi AC, Putignano G, Nicolardi V, Selvaggi L. A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III—IV endometriosis. Eur J Obstet Gynecol Reprod Biol. 2008;136:194-198. 
  21. Gong L, Zhang S, Han Y, Long Q, Zou S, Cao Y. Initiation of GnRH agonist treatment on 3-5 days postoperatively in endometriosis patients: a randomized controlled trial. J Clin Pharmacol. 2015;55:8:848-853.  https://doi.org/10.1002/jcph.485
  22. Zheng Q, Mao H, Xu Y, Zhao J, Wei X, Liu P. Can postoperative GnRH agonist treatment prevent endometriosis recurrence? A meta-analysis. Arch Gynecol Obstet. 2016;294:1:201-207.  https://doi.org/10.1007/s00404-016-4085-y
  23. Casteel CO, Singh G. Physiology, gonadotropin-releasing hormone. 2022 May 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2022. PMID: 32644418.
  24. Bedaiwy MA, Allaire C, Alfaraj S. Long-term medical management of endometriosis with dienogest and with a gonadotropin-releasing hormone agonist and add-back hormone therapy. Fertil Steril. 2017;107:3:537-548.  https://doi.org/10.1016/j.fertnstert.2016.12.024
  25. Lo SH. Tensin. Int J Biochem Cell Biol. 2004;36:1:31-34.  https://doi.org/10.1016/s1357-2725(03)00171-7
  26. Chen H, Duncan IC, Bozorgchami H, Lo SH. Tensin1 and a previously undocumented family member, tensin2, positively regulate cell migration. Proc Natl Acad Sci USA. 2002;99:733-738. 
  27. Rahmawati E, Yang WV, Lei YP, Maurya PK, Chen HW, Tzeng CR. Gonadotropin-releasing hormone agonist induces downregulation of tensin 1 in women with endometriosis. Acta Obstet Gynecol Scand. 2019;98:2:222-231.  https://doi.org/10.1111/aogs.13481
  28. Maggi R, Cariboni AM, Marelli MM, Moretti RM, Andrè V, Marzagalli M, Limonta P. GnRH and GnRH receptors in the pathophysiology of the human female reproductive system. Hum Reprod Update. 2016;22:3:358-381.  https://doi.org/10.1093/humupd/dmv059
  29. Hsu CC, Lin YS, Wang ST, Huang KE. Immunomodulation in women with endometriosis receiving GnRH agonist. Obstet Gynecol. 1997;89:6:993-998.  https://doi.org/10.1016/s0029-7844(97)00145-2
  30. Khan KN, Kitajima M, Hiraki K, Fujishita A, Sekine I, Ishimaru T, Masuzaki H. Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy. Hum Reprod. 2010;25:3:642-653.  https://doi.org/10.1093/humrep/dep437
  31. Adamyan LV, Arslanyan KN, Kharchenko EI, Loginova ON. Modern trends in the treatment of endometriosis. Russian Journal of Human Reproduction. 2019;25:6:58-66. (In Russ.). https://doi.org/10.17116/repro20192506158
  32. Ministry of Health of the Russian Federation. Clinical recommendations. Uterine myoma. 2020. (In Russ.).
  33. Välimäki N, Kuisma H, Pasanen A, Heikinheimo O, Sjöberg J, Bützow R, Sarvilinna N, Heinonen H-R , Tolvanen J, Bramante S, Tanskanen T, Auvinen J, Uimari O, Alkodsi A, Lehtonen R, Kaasinen E, Palin K, Aaltonen LA. Genetic predisposition to uterine leiomyoma is determined by loci for genitourinary development and genome stability. Elife. 2018;7:e37110.
  34. Tikhomirov AL. Gonadotropic releasing hormone agonists in the treatment of uterine fibroids. RMZh. Mat’ i ditya. 2010;18:4:188. (In Russ.).
  35. De La Cruz MS, Buchanan EM. Uterine fibroids: Diagnosis and treatment. Am Fam Physician. 2017;95:2:100-107. 
  36. Broekmans FJ. GnRH agonists and uterine leiomyomas. Hum Reprod. 1996;11 Suppl 3:3-25.  https://doi.org/10.1093/humrep/11.suppl_3.3
  37. Vollenhoven BJ, Pearce P, Herington AC, Healy DL. Steroid receptor binding and messenger RNA expression in fibroids from untreated and gonadotrophin-releasing hormone agonist pretreated women. Clin Endocrinol (Oxf). 1994;40:537-544. 
  38. Kamath MS, Kalampokas EE, Kalampokas TE. Use of GnRH analogues pre-operatively for hysteroscopic resection of submucous fibroids: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2014;177:11-18.  https://doi.org/10.1016/j.ejogrb.2014.03.009
  39. Zhu XQ, Shi YF, Cheng XD, Zhao CL, Wu YZ. Immunohistochemical markers in differential diagnosis of endometrial stromal sarcoma and cellular leiomyoma. Gynecol Oncol. 2004;92:71-79. 
  40. Khan KN, Kitajima M, Hiraki K, Fujishita A, Nakashima M, Masuzaki H. Decreased expression of human heat shock protein 70 in the endometria and pathological lesions of women with adenomyosis and uterine myoma after GnRH agonist therapy. Eur J Obstet Gynecol Reprod Biol. 2015;187:6-13.  https://doi.org/10.1016/j.ejogrb.2015.01.012
  41. Donnez J, Schrurs B, Gillerot S, Sandow J, Clerckx F. Treatment of uterine fibroids with implants of gonadotropin-releasing hormone agonist: assessment by hysterography. Fertil Steril. 1989;51:6:947-950.  https://doi.org/10.1016/s0015-0282(16)60723-9
  42. Mäkinen N, Mehine M, Tolvanen J, Kaasinen E, Li Y, Lehtonen HJ, Gentile M, Yan J, Enge M, Taipale M, Aavikko M, Katainen R, Virolainen E, Böhling T, Koski TA, Launonen V, Sjöberg J, Taipale J, Vahteristo P, Aaltonen LA. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science. 2011;334:252-255. 
  43. Asano R, Asai-Sato M, Matsukuma S, Mizushima T, Taguri M, Yoshihara M, Inada M, Fukui A, Suzuki Y, Miyagi Y, Miyagi E. Expression of erythropoietin messenger ribonucleic acid in wild-type MED12 uterine leiomyomas under estrogenic influence: new insights into related growth disparities. Fertil Steril. 2019;111:178-185. 
  44. He C, Nelson W, Li H, Xu Y-D, Dai X-J, Wang Y-X, Ding Y-B, Li Y-P, Li T. Frequency of MED12 mutation in relation to tumor and patient’s clinical characteristics: a meta-analysis. Reprod Sci. 2022;29:357-365. 
  45. Nagai K, Asano R, Sekiguchi F, Asai-Sato M, Miyagi Y, Miyagi E. MED12 mutations in uterine leiomyomas: prediction of volume reduction by gonadotropin-releasing hormone agonists. Am J Obstet Gynecol. 2023;228:2)207.e1-207.e9.  https://doi.org/10.1016/j.ajog.2022.09.024
  46. Kim EH, Kim JY, Lee YH, Chong GO, Park JY, Hong DG. Comparison of estrogen receptor-α, progesterone receptor and calponin expression in gonadotrophin-releasing hormone agonist-sensitive and -resistant uterine fibroids. Obstet Gynecol Sci. 2014;57:2:144-150.  https://doi.org/10.5468/ogs.2014.57.2.144
  47. Chung YJ, Chae B, Kwak SH, Song JY, Lee AW, Jo HH, Lew YO, Kim JH, Kim MR. Comparison of the inhibitory effect of gonadotropin releasing hormone (GnRH) agonist, selective estrogen receptor modulator (SERM), antiprogesterone on myoma cell proliferation in vitro. Int J Med Sci. 2014;11:3:276-281.  https://doi.org/10.7150/ijms.7627
  48. Lethaby A, Vollenhoven B, Sowter M. Efficacy of pre-operative gonadotrophin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy. BJOG. 2002;109:10:1097-1108.
  49. Healy DL, Fraser HM, Lawson SL. Shrinkage of a uterine fibroid after subcutaneous infusion of a LHRH agonist. Br Med J. 1984;209:6454:1267-1268.
  50. Lethaby A, Vollenhoven B, Sowter M. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. Cochrane Database Syst Rev. 2000;2:CD000547. Update in: Cochrane Database Syst Rev. 2001;2:CD000547. https://doi.org/10.1002/14651858.CD000547
  51. Imankulova B, Mereke A, Kamzaeva N, Ukybassova T. Comparing the use of uterine artery embolization to gonadotropin-releasing hormone agonists in shrinking fibroid size: A Pilot study in Kazakhstan. Cent Asian J Glob Health. 2015;4:1:232.  https://doi.org/10.5195/cajgh.2015.232
  52. Ministry of Health of the Russian Federation. Clinical recommendations. Endometrial hyperplasia. 2021. (In Russ.).
  53. Agorastos T, Vaitsi V, Paschopoulos M, Vakiani A, Zournatzi-Koiou V, Saravelos H, Kostopoulou E, Constantinidis T, Dinas K, Vavilis D, Lolis D, Bontis J. Prolonged use of gonadotropin-releasing hormone agonist and tibolone as add-back therapy for the treatment of endometrial hyperplasia. Maturitas. 2004;48:2:125-132. 
  54. Agorastos T, Bontis J, Vakiani A, Vavilis D, Constantinidis T. Treatment of endometrial hyperplasias with gonadotropin-releasing hormone agonists: pathological, clinical, morphometric, and DNA-cytometric data. Gynecol Oncol. 1997;65:102-114. 
  55. Hutt S, Tailor A, Ellis P, Michael A, Butler-Manuel S, Chatterjee J. The role of biomarkers in endometrial cancer and hyperplasia: a literature review. Acta Oncol. 2019;58:3:342-352.  https://doi.org/10.1080/0284186X.2018.1540886
  56. Allison KH, Tenpenny E, Reed SD, Swisher EM, Garica RL. Immunohistochemical markers in endometrial hyperplasia: is there a panel with promise? A review. Appl Immunohistochem Mol Morphol. 2008;16:329-343. 
  57. Nagai N, Oshita T, Mukai K, Shiroyama Y, Shigemasa K, Ohama K. GnRH agonist inhibits human telomerase reverse transcriptase mRNA expression in endometrial cancer cells. Int J Mol Med. 2002;10:5:593-597. 
  58. Chandra V, Kim JJ, Benbrook DM, Dwivedi A, Rai R. Therapeutic options for management of endometrial hyperplasia. J Gynecol Oncol. 2016;27:1:e8.  https://doi.org/10.3802/jgo.2016.27.e8
  59. Chen J, Cao D, Yang J, Yu M, Zhou H, Cheng N, Wang J, Zhang Y, Peng P, Shen K. Fertility-sparing treatment for endometrial cancer or atypical endometrial hyperplasia patients with obesity. Front Oncol. 2022;12:812346. https://doi.org/10.3389/fonc.2022.812346
  60. Chen JY, Cao DY, Zhou HM, Yu M, Yang JX, Wang JH, Zhang Y, Cheng NH, Peng P. GnRH-a combined fertility-sparing re-treatment in women with endometrial carcinoma or atypical endomertial hyperplasia who failed to oral progestin therapy. Zhonghua Fu Chan Ke Za Zhi. 2021;56:8:561-568. Chinese. https://doi.org/10.3760/cma.j.cn112141-20210603-00298
  61. Pashov AI, Sivova EN, Volkova LV, Rachkovskaya VV. Experience of conservative treatment of atypical hyperplasia and endometrial carcinoma: immunohistochemical aspects. Akusherstvo i ginekologiya. 2023;4:155-160. (In Russ.).
  62. Pashov AI, Sivova EN, Metrinskii YaYu. Combined use of gonadotropin-releasing hormone agonists and the intrauterine levonorgestrel-releasing system in the treatment of atypical endometrial hyperplasia in women of reproductive age. Doktor.Ru. 2020;19:1:58-61. (In Russ.).
  63. Ministry of Health of the Russian Federation. Clinical recommendations. Endometrial cancer and uterine sarcoma. 2021. (In Russ.).
  64. Van den Bosch T, Coosemans A, Morina M, Timmerman D, Amant F. Screening for uterine tumours. Best Pract Res Clin Obstet Gynaecol. 2012;26:2:257-266. 
  65. Dinkelspiel HE, Wright JD, Lewin SN, Herzog TJ. Contemporary clinical management of endometrial cancer. Obstet Gynecol Int. 2013;2013:583891.
  66. Pashov AI, Tskhai VB. Independent hormone therapy of initial endometrial cancer in the reproductive age. Acta Biomedica Scientifica. 2010;6-2:49-51. (In Russ.).
  67. Pashov AI, Tskhai VB, Sivova EN. Complex hormone therapy with GnRH agonists and the intrauterine levonorgestrel–releasing system for complex atypical hyperplasia and endometrial adenocarcinoma: a pilot prospective observational study. Zlokachestvennye opukholi. 2012;2:1:15-17. (In Russ.).
  68. Nechushkina VM, Kolomiets LA, Kravets OA, Morkhov KYu, Novikova EG, Novikova OV, Tyulyandina AS, Ul’rikh EA, Fedenko AA, Khokhlova SV. Practical recommendations for the drug treatment of uterine cancer and uterine sarcoma. Malignant tumors: Practical recommendations of RUSSCO #3s2. 2022;12:260-275. (In Russ.).
  69. Petrozhitskaya AA, Tandelov RK, Zaitsev NA, Morkhov KY. Organ-preserving treatment of atypical hyperplasia and endometrial cancer: current trends. Zlokachestvennye opukholi. 2023;13:2:5. (In Russ.).
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.